Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Langenbeck's Archives of Surgery
Erschienen in: Langenbeck's Archives of Surgery 5/2017

11.05.2017 | ORIGINAL ARTICLE

Treatment and outcomes of recurrent hepatocellular carcinomas

verfasst von: Gaëtan-Romain Joliat, Pierre Allemann, Ismail Labgaa, Nicolas Demartines, Nermin Halkic

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Surgery is one of the best options for curative treatment of hepatocellular carcinomas (HCC). Recurrences are nevertheless common (45–75%). This study aimed to compare overall survival (OS) of patients with recurrent HCC after primary resection to OS of patients without recurrence.

Methods

A retrospective review of all HCC patients operated between 1993 and 2015 was performed. Median and 5-year OS were calculated.

Results

This study included 147 HCC patients. Sixty-seven patients presented a recurrence (46%). Patients with recurrence had a worse prognosis than those without recurrence (median OS 63 vs. 82 months, 5-year OS 47 vs. 54%, p = 0.036). First-line performed treatments were radiofrequency ablation (18, RFA), chemo-embolization (16, TACE), repeat hepatectomy (10), systemic chemotherapy (4), radio-embolization (1), and alcoholization (1). Palliative care was performed in 17 patients. Median OS of patients treated by RFA, TACE, or repeat hepatectomy were similar (77, 71, and 84 months, p = 0.735). Patients treated with chemotherapy/palliative care had lower median OS compared to interventional treatments (20 vs. 77 months, p < 0.0001).

Conclusions

Recurrence after surgical HCC resection is frequent and negatively impacts OS. Interventional treatments of recurrences offered improved outcomes compared to medical care. In selected patients, RFA, TACE, and repeat hepatectomy allowed similar OS as non-recurrent cases.
Literatur
1.
2.
Lafaro K, Grandhi MS, Herman JM, Pawlik TM (2016) The importance of surgical margins in primary malignancies of the liver. J Surg Oncol 113:296–303CrossRefPubMed
3.
Sangiovanni A, Colombo M (2016) Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 36(Suppl 1):124–129CrossRefPubMed
4.
Liu H, Wang Z-G, Fu S-Y, Li A-J, Pan Z-Y, Zhou W-P et al (2016) Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 103:348–356CrossRefPubMed
5.
Meniconi RL, Komatsu S, Perdigao F, Boëlle P-Y, Soubrane O, Scatton O (2015) Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 157:454–462CrossRefPubMed
6.
An HJ, Shin WY, Lee K-Y, Ahn S-I (2015) A comparison of the risk factors of intrahepatic recurrence, early recurrence, and multiple recurrences after resection for single nodular hepatocellular carcinoma. Korean J Hepato-Biliary-Pancreat Surg 19:89–97CrossRef
7.
Hwang S, Lee Y-J, Kim K-H, Ahn C-S, Moon D-B, Ha T-Y et al (2015) The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg 19:1281–1290CrossRefPubMed
8.
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955CrossRefPubMed
9.
Wang D-Y, Liu L, Qi X-S, Su C-P, Chen X, Liu X et al (2015) Hepatic re-resection versus transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis. Asian Pac J Cancer Prev 16:5573–5578CrossRefPubMed
10.
Yamashita Y-I, Yoshida Y, Kurihara T, Itoh S, Harimoto N, Ikegami T et al (2015) Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: repeat hepatectomy versus salvage living donor liver transplantation. Liver Transplant 21:961–968CrossRef
11.
12.
Song KD, Lim HK, Rhim H, Lee MW, Kim Y-S, Lee WJ et al (2015) Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection: a propensity score matching study. Radiology 275:599–608CrossRefPubMed
13.
Fukuhara T, Aikata H, Hyogo H, Honda Y, Morio K, Morio R et al (2015) Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: comparison with primary cases. Eur J Radiol 84:1540–1545CrossRefPubMed
14.
Chen X, Chen Y, Li Q, Ma D, Shen B, Peng C (2015) Radiofrequency ablation versus surgical resection for intrahepatic hepatocellular carcinoma recurrence: a meta-analysis. J Surg Res 195:166–174CrossRefPubMed
15.
Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R et al (2011) Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transplant 17(Suppl 2):S44–S57CrossRef
16.
Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral
17.
Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BPL, Breitenstein S, et al (2014) The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials. Ann Surg 260:757-762-763
18.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655CrossRefPubMed
19.
Zhang X, Li C, Wen T, Yan L, Li B, Yang J et al (2015) Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J Gastroenterol Hepatol 27:933–940CrossRefPubMed
20.
Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW et al (2007) Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141:330–339CrossRefPubMed
21.
Hou Y-F, Li B, Wei Y-G, Yang J-Y, Wen T-F, Xu M-Q et al (2015) Second hepatectomy improves survival in patients with microvascular invasive hepatocellular carcinoma meeting the Milan criteria. Medicine (Baltimore) 94:e2070CrossRef
22.
Thomasset SC, Dennison AR, Garcea G (2015) Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg 39:1150–1160CrossRefPubMed
23.
Zhang C, Zhang J, Li X, Li L, Li X, Zhou X (2015) Is radiofrequency ablation equal to surgical re-resection for recurrent hepatocellular carcinoma meeting the Milan criteria? A meta-analysis. J BUON 20:223–230PubMed
24.
Jin Y-J, Lee J-W, Lee OH, Chung HJ, Kim YS, Lee JI et al (2014) Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion. J Gastroenterol Hepatol 29:1056–1064CrossRefPubMed
25.
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207CrossRefPubMed
26.
Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD et al (2006) Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 202:275–283CrossRefPubMed
27.
28.
Ali MA, Li W-F, Wang J-H, Lin C-C, Chen Y-J, Lin T-L et al (2016) Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from southern Taiwan. HPB 18:851–860CrossRefPubMedPubMedCentral
29.
Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D et al (2016) Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget 7:83806–83816PubMedPubMedCentral
30.
Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B et al (2016) Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within Barcelona clinic liver cancer stage 0/a: a retrospective comparative study. J Vasc Interv Radiol 27:1829–1836CrossRefPubMed
31.
Zhang J, Zhou Z-G, Huang Z-X, Yang K-L, Chen J-C, Chen J-B et al (2016) Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer 35:25CrossRefPubMedPubMedCentral
32.
Zou Q, Li J, Wu D, Yan Z, Wan X, Wang K et al (2016) Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg Oncol 23:2618–2626CrossRefPubMed
33.
Koh PS, Chan ACY, Cheung TT, Chok KSH, Dai WC, Poon RTP et al (2016) Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB 18:72–78CrossRefPubMedPubMedCentral
34.
Yong C-C, Tsai M-C, Lin C-C, Wang C-C, Lu S-N, Hung C-H et al (2016) Comparison of salvage living donor liver transplantation and local regional therapy for recurrent hepatocellular carcinoma. World J Surg 40:2472–2480CrossRefPubMed
35.
Zu Q-Q, Liu S, Zhou C-G, Yang Z-Q, Xia J-G, Zhao L-B et al (2015) Chemoembolization of recurrent hepatoma after curative resection: prognostic factors. AJR Am J Roentgenol 204:1322–1328CrossRefPubMed
36.
Wang K, Liu G, Li J, Yan Z, Xia Y, Wan X et al (2015) Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol 41:236–242CrossRefPubMed
37.
Mise Y, Hasegawa K, Shindoh J, Ishizawa T, Aoki T, Sakamoto Y et al (2015) The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 262:347–357CrossRefPubMed
38.
Yamashita Y-I, Imai D, Bekki Y, Takeishi K, Tsujita E, Ikegami T et al (2014) Surgical outcomes of anatomical resection for solitary recurrent hepatocellular carcinoma. Anticancer Res 34:4421–4426PubMed
39.
Cheng Y-C, Chen T-W, Fan H-L, Yu C-Y, Chang H-C, Hsieh C-B (2014) Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation. Ann Transplant 19:309–301CrossRefPubMed
Metadaten
Titel
Treatment and outcomes of recurrent hepatocellular carcinomas
verfasst von
Gaëtan-Romain Joliat
Pierre Allemann
Ismail Labgaa
Nicolas Demartines
Nermin Halkic
Publikationsdatum
11.05.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 5/2017
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1582-9

Weitere Artikel der Ausgabe 5/2017

Langenbeck's Archives of Surgery 5/2017 Zur Ausgabe

ORIGINAL ARTICLE

Outpatient Drainmanagement of patients with clinically relevant Postoperative Pancreatic Fistula (POPF)

REVIEW ARTICLE

Portal vein embolization in extended liver resection

How-I-Do-It Articles

The feasibility of laparoscopic pancreaticoduodenectomy—a stepwise procedure and learning curve

ORIGINAL ARTICLE

The extent of surgery in thyroglossal cyst carcinoma

ORIGINAL ARTICLE

Posterior retroperitoneoscopic adrenal surgery for clinical and subclinical Cushing’s syndrome in patients with bilateral adrenal disease

ORIGINAL ARTICLE

Implications of SDHB genetic testing in patients with sporadic pheochromocytoma

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.